<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892359</url>
  </required_header>
  <id_info>
    <org_study_id>1.1 - Leitner</org_study_id>
    <nct_id>NCT00892359</nct_id>
  </id_info>
  <brief_title>Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)</brief_title>
  <official_title>The Pharmacokinetics of Anidulafungin During Continuous Venovenous Hemofiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the pharmacokinetics of anidulafungin during continuous&#xD;
      venovenous hemofiltration.&#xD;
&#xD;
      Background: Anidulafungin is a cyclic lipopeptide antifungal agent of the echinocandin class.&#xD;
      Members of this class of antifungal agents are known to inhibit the synthesis of glucan&#xD;
      polymers in fungal cell walls. The spectrum of activity of anidulafungin includes Candida&#xD;
      (all species, including strains resistant to fluconazole), Aspergillus, and Pneumocystis.&#xD;
&#xD;
      In intensive care patients continuous venovenous haemodiafiltration (CVVHF) is a&#xD;
      well-established extracorporal renal replacement therapy with a high clearance rate.&#xD;
&#xD;
      Pharmacokinetic studies of antifungal agents in critically ill patients treated with CVVHF&#xD;
      are rare. No data about anidulafungin in CVVHF are available although intensive care patients&#xD;
      are perfect candidates for anidulafungin treatment due to their high risk profile for&#xD;
      systemic fungal infections.&#xD;
&#xD;
      Study objective: The study is conducted to investigate the pharmacokinetics of anidulafungin&#xD;
      during CVVHF in critically ill patients.&#xD;
&#xD;
      Study design: open, 1 arm&#xD;
&#xD;
      Study population: 10 critically ill adult patients administered to the ICU with acute renal&#xD;
      failure and suspected or proven fungal infection.&#xD;
&#xD;
      Treatment/Dosage/Route: On the first day 200 mg of anidulafungin will be administered&#xD;
      intravenously over 3 hours (loading dose). The following days 100 mg of anidulafungin will be&#xD;
      administered intravenously over 1.5 hours.&#xD;
&#xD;
      Main outcome variables: The following pharmacokinetic parameters will be determined: area&#xD;
      under the curve (AUC), half-live (t1/2), maximum plasma concentration (Cmax) and elimination&#xD;
      fraction.&#xD;
&#xD;
      Methods: High pressure liquid chromatography (HPLC) will be used to determine anidulafungin&#xD;
      concentrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anidulafungin area under the curve (AUC), half-live (t1/2), maximum plasma concentration (Cmax) and elimination fraction.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Renal Failure</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Anidulafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin</intervention_name>
    <description>treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.</description>
    <arm_group_label>Anidulafungin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19 to 70 years&#xD;
&#xD;
          -  Suspected or proven infection requiring parenteral antifungal therapy.&#xD;
&#xD;
          -  Continuous venovenous hemofiltration because of an acute renal failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypersensitivity to echinocandins.&#xD;
&#xD;
          -  An expected survival of less than three days.&#xD;
&#xD;
          -  Known alcohol dependency, epilepsy, pregnancy or liver failure.&#xD;
&#xD;
          -  Neutropenic patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Judith M Leitner, M.D.</last_name>
    <phone>+43140400</phone>
    <phone_ext>4440</phone_ext>
    <email>judith.leitner@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith M Leitner, M.D.</last_name>
      <phone>+43140400</phone>
      <email>judith.leitner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Judith M Leitner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>May 1, 2009</last_update_submitted>
  <last_update_submitted_qc>May 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Florian Thalhammer, M.D.</name_title>
    <organization>Medical University of Vienna</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>hemofiltration</keyword>
  <keyword>anidulafungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anidulafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

